Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study
Drug Design Development and Therapy December 1, 2019 Jing Wang, Jie Huang, Shuang Yang et al. 214 citations
A single 0.5 mg/kg dose of esketamine is generally safe and tolerated in Chinese patients undergoing painless gastroscopy. Compared with 1 mg/kg racemic ketamine, esketamine provides a shorter recovery time (9 minutes vs. 13 minutes) and orientation recovery time (11.5 minutes vs. 17 minutes). Adverse event rates were 75.0% for esketamine and 87.5% for racemic ketamine, with dizziness, agitation, nausea, vomiting, headache, and fatigue as main reactions; no serious adverse events occurred. Clearance of esketamine was similar between groups (18.1 and 18.4 mL/min·kg), but in the racemic group esketamine cleared faster than R-ketamine. Gender did not affect pharmacokinetics.